ES2071836T3 - Utilizacion de xantinas, eventualmente incorporadas en liposomas, para favorecer la pigmentacion de la piel o de los cabellos. - Google Patents

Utilizacion de xantinas, eventualmente incorporadas en liposomas, para favorecer la pigmentacion de la piel o de los cabellos.

Info

Publication number
ES2071836T3
ES2071836T3 ES90917311T ES90917311T ES2071836T3 ES 2071836 T3 ES2071836 T3 ES 2071836T3 ES 90917311 T ES90917311 T ES 90917311T ES 90917311 T ES90917311 T ES 90917311T ES 2071836 T3 ES2071836 T3 ES 2071836T3
Authority
ES
Spain
Prior art keywords
skin
pigmentation
liposomes
hair
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917311T
Other languages
English (en)
Inventor
Frederic Bonte
Marc Dumas
Alain Meybeck
Christian Marechal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LVMH Recherche GIE
Original Assignee
LVMH Recherche GIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LVMH Recherche GIE filed Critical LVMH Recherche GIE
Application granted granted Critical
Publication of ES2071836T3 publication Critical patent/ES2071836T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE XANTINAS, EVENTUALMENTE INCORPORADAS EN LIPOSOMAS, PARA FAVORECER LA PIGMENTACION DE LA PIEL O DEL CABELLO. ESTA XANTINA TIENE LA FORMULA (I), O UNA SAL DE ESTA, O UN EXTRACTO VEGETAL QUE LA CONTIENE, EN LA QUE, EN PARTICULAR R SUB 3 Y R SUB 4 REPRESENTAN CADA UNO UN ATOMO DE HIDROGENO Y QUE R SUB 1 Y R SUB 2 IDENTICOS O DIFERENTES REPRESENTAN CADA UNO, UN ATOMO DE HIDROGENO O UN RADICAL ALQUILO QUE TIENE PREFERENTEMENTE DE 1 A 4 ATOMOS DE CARBONO. ESTA XANTINA, EVENTUALMENTE INCORPORADA EN LIPOSOMAS, SE UTILIZA PARA LA PREPARACION DE UNA COMPOSICION COSMETICA O FARMACEUTICA, EN PARTICULAR DERMATOLOGICA PARA LA PIGMENTACION DE LA PIEL O DEL CABELLO O PARA REFORZAR LAS DEFENSAS NATURALES DE LA PIEL CONTRA LA RADIACION SOLAR.
ES90917311T 1989-11-28 1990-11-16 Utilizacion de xantinas, eventualmente incorporadas en liposomas, para favorecer la pigmentacion de la piel o de los cabellos. Expired - Lifetime ES2071836T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR898915653A FR2654935B1 (fr) 1989-11-28 1989-11-28 Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.

Publications (1)

Publication Number Publication Date
ES2071836T3 true ES2071836T3 (es) 1995-07-01

Family

ID=9387873

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90917311T Expired - Lifetime ES2071836T3 (es) 1989-11-28 1990-11-16 Utilizacion de xantinas, eventualmente incorporadas en liposomas, para favorecer la pigmentacion de la piel o de los cabellos.

Country Status (9)

Country Link
US (1) US5470579A (es)
EP (1) EP0502043B1 (es)
JP (1) JPH05504129A (es)
AT (1) ATE119027T1 (es)
AU (1) AU650250B2 (es)
DE (1) DE69017467T2 (es)
ES (1) ES2071836T3 (es)
FR (1) FR2654935B1 (es)
WO (1) WO1991007945A1 (es)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540914A (en) * 1989-12-15 1996-07-30 The Board Of Regents Of The University Of Oklahoma Pigmentation enhancer and method
US6733776B1 (en) 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
FR2699169B1 (fr) * 1992-12-16 1995-02-03 Oreal Nouveaux sels d'amines primaires dérivés d'acides aminés à groupement uréthanne, et leur utilisation dans des compositions cosmétiques.
CA2159626C (en) * 1993-04-02 2001-10-02 Lingna Li Method for delivering beneficial compositions to hair follicles
US7556825B2 (en) 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
AU5959094A (en) * 1993-12-21 1995-07-10 Board Of Regents Of The University Of Oklahoma, The Pigmentation enhancer and method
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5626854A (en) * 1994-03-17 1997-05-06 Kao Corporation Bath composition
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
DE69531506T2 (de) * 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
JP2001523213A (ja) * 1994-12-13 2001-11-20 ユーロ−セルティーク，エス．エイ． 三置換チオキサンチン類
US6844326B2 (en) 1995-06-07 2005-01-18 Anticancer, Inc. Treatment of alopecia
DE19606545A1 (de) * 1996-02-22 1997-08-28 Wella Ag Kosmetisches Mittel mit einem Gehalt an Ilexharz, Verfahren zur Gewinnung von Ilexharz und durch dieses Verfahren erhältliches Ilexharz
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5998423A (en) * 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
US5811101A (en) * 1997-04-29 1998-09-22 Waltman Pharmaceuticals Incorporated Composition for treating acne
FR2768343B1 (fr) * 1997-09-18 2000-03-10 Oreal Utilisation d'au moins un extrait d'au moins un vegetal du genre chrysanthemum pour favoriser la pigmentation de la peau et/ou des cheveux
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
WO1999031101A1 (en) * 1997-12-17 1999-06-24 University Of South Florida Adenosine receptor antagonists with improved bioactivity
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US6267948B1 (en) * 1998-04-06 2001-07-31 Applied Genetics Incorporated Dermatics Dermatological formulations and methods
US6815446B1 (en) * 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
FR2810242B1 (fr) * 2000-06-16 2003-01-17 Nuxe Lab Composition cosmetique et/ou dermatologique a base d'extraits de cacao
EP1301187B1 (en) * 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
FR2812873B1 (fr) * 2000-08-11 2003-08-01 Barry Callebaut France Procede de production de polyphenols a partir de feves de cacao
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
FR2816852B1 (fr) * 2000-11-21 2005-08-26 Nuxe Lab Association stabilisee d'un colorant et d'un emulsionnant, composition cosmetique et/ou dermatologique la contenant et procede de preparation
EA007485B1 (ru) * 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
FR2823112B1 (fr) * 2001-04-09 2004-03-05 Oreal Produit bronzant et filtrant
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
DE10150412A1 (de) 2001-10-11 2003-04-17 Beiersdorf Ag Verwendung einer oder mehreren Substanzen, gewählt aus der Gruppe der Pyrimidine und Purine in kosmetischen Zubereitungen zur Bräunung der Haut
DE10150445A1 (de) * 2001-10-12 2003-04-17 Beiersdorf Ag Verwendung einer oder mehreren Substanzen, gewählt aus der Gruppe der Pyrimidine und Purine in kosmetischen Zubereitungen zur Haarfärbung
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
BR0311568A (pt) * 2002-07-05 2005-03-01 Unilever Nv Método de tratamento de cabelo e uso de uma composição
MEP59708A (en) * 2002-08-21 2011-05-10 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2013251292B2 (en) * 2002-08-21 2015-12-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0411168B1 (pt) * 2003-05-29 2013-11-05 Composição para o tratamento dos cabelos, usos da composição e método de tratamento dos cabelos.
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
FR2885299B1 (fr) * 2005-05-03 2009-11-20 Nuxe Lab Utilisation de polyphenols de cacao pour reguler la pigmentation de la peau
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070183995A1 (en) * 2006-02-09 2007-08-09 Conopco, Inc., D/B/A Unilever Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same
WO2007122251A2 (en) * 2006-04-25 2007-11-01 Symrise Gmbh & Co. Kg Synergistic mixture of glycosyl flavanones and xanthines
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
FR2904556B1 (fr) * 2006-08-03 2013-12-27 Soc Extraction Principes Actif Utilisation d'un extrait de pois en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
WO2008015342A2 (fr) * 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
FR2904541B1 (fr) * 2006-08-03 2011-05-27 Soc Extraction Principes Actif Utilisation d'un extrait de soja en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
FR2904544A1 (fr) * 2006-08-03 2008-02-08 Soc Extraction Principes Actif Utilisation d'un extrait de haricot en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
FR2904542B1 (fr) * 2006-08-03 2011-06-24 Soc Extraction Principes Actif Utilisation d'un extrait de feves de cacao en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
WO2008015341A2 (fr) * 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
EP2057160A1 (en) * 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
US20080059313A1 (en) * 2006-08-30 2008-03-06 Oblong John E Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair
DE102006050984A1 (de) * 2006-10-26 2008-04-30 Henkel Kgaa Leistungsgesteigerte kosmetische Mittel mit Purin und/oder Purinderivaten
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
CA2700729A1 (en) * 2007-10-19 2009-04-23 The University Of Tokyo Therapeutic agent for vitiligo and method of accelerating pigmentation
GB0801119D0 (en) 2008-01-22 2008-02-27 Barry Callebaut Ag Composition
CN104825341A (zh) * 2008-02-29 2015-08-12 宝洁公司 毛发护理组合物和增加毛发直径的方法
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20090263518A1 (en) 2008-04-17 2009-10-22 Barry Callebaut Ag Composition and Uses Thereof
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN103816158A (zh) * 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
DE102009044977A1 (de) 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Kosmetisches Mittel enthaltend Purin und/oder ein Purinderivat und Sclareol
DE102009044976A1 (de) 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Verwendung von Purin und/oder einem Purinderivat und mindestens einem Oligonukleotid zur Beeinflussung des natürlichen Pigmentierungsprozesses
DE102009044964A1 (de) 2009-09-24 2011-03-31 Henkel Ag & Co. Kgaa Verwendung einer Kombination aus Carnitin und/oder eines Carnitin-Derivats mit Purin und/oder einem Purin-Derivat zur Beeinflussung des natürlichen Pigmentierungsprozesses
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
DE102010043068A1 (de) 2010-10-28 2012-05-03 Henkel Ag & Co. Kgaa Verwendung von Purin und/oder einem Purinderivat und mindestens einem Biochinon zur Beeinflussung des natürlichen Pigmentierungsprozesses
DE102010043069A1 (de) 2010-10-28 2012-05-03 Henkel Ag & Co. Kgaa Verwendung von Purin und/oder einem Purinderivat und mindestens einer Aminosäure zur Beeinflussung des natürlichen Pigmentierungsprozesses
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
FR2973697B1 (fr) 2011-04-05 2013-10-25 Nuxe Lab Composition a base d'huile de chaulmoogra et de tribulus terrestris pour la pigmentation de la peau.
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
FR2978659B1 (fr) 2011-08-05 2014-01-10 Oreal Utilisation de composes cannabinoides pour stimuler la melanogenese
DE102011087135A1 (de) 2011-11-25 2012-07-26 Henkel Ag & Co. Kgaa Verwendung von Rutin zur Beeinflussung des natürlichen Pigmentierungsprozesses
DE102011088009A1 (de) 2011-12-08 2013-06-13 Henkel Ag & Co. Kgaa Theophyllinderivate zur Repigmentierung von keratinhaltigen Fasern
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
FR2999932B1 (fr) 2012-12-21 2020-01-31 Société des Produits Nestlé S.A. Utilisation de microorganismes probiotiques comme agent favorisant la synthese de melanine
FR2999931A1 (fr) 2012-12-21 2014-06-27 Oreal Utilisation de microorganismes probiotiques comme agent favorisant la synthese de melanine
US10123966B2 (en) 2013-05-16 2018-11-13 The Procter And Gamble Company Hair thickening compositions and methods of use
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
DE102014212921A1 (de) 2014-07-03 2016-01-07 Henkel Ag & Co. Kgaa Verwendung von speziellen Oligopeptiden zur Stimulierung des natürlichen Pigmentierungsprozesses in Hautanhangsgebilden
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
EP4173616A1 (en) * 2021-10-29 2023-05-03 Hospital Clínic de Barcelona Uric acid liposomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107306A (en) * 1973-01-16 1978-08-15 The Regents Of The University Of Michigan Process for treating proliferative skin disease
FR2609395B1 (fr) * 1988-02-23 1992-01-10 Serobiologiques Lab Sa Utilisation de bases xanthiques comme principe actif d'une composition pharmaceutique, notamment dermatologique, ou cosmetique, composition notamment utile comme matiere de base pour la preparation de composition pharmaceutique ou cosmetique et composition pharmaceutique ou cosmetique ainsi preparee
FR2631234B1 (fr) * 1988-05-10 1990-09-14 Dior Christian Parfums Composition cosmetique ou dermatologique, notamment a action amincissante ou anti-cellulitique contenant des extraits de cola sous forme libre ou sous forme liposomale

Also Published As

Publication number Publication date
AU650250B2 (en) 1994-06-16
EP0502043A1 (fr) 1992-09-09
WO1991007945A1 (fr) 1991-06-13
FR2654935A1 (fr) 1991-05-31
JPH05504129A (ja) 1993-07-01
DE69017467D1 (de) 1995-04-06
DE69017467T2 (de) 1995-10-19
AU6745990A (en) 1991-06-26
ATE119027T1 (de) 1995-03-15
EP0502043B1 (fr) 1995-03-01
FR2654935B1 (fr) 1994-07-01
US5470579A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
ES2071836T3 (es) Utilizacion de xantinas, eventualmente incorporadas en liposomas, para favorecer la pigmentacion de la piel o de los cabellos.
ES2081110T3 (es) Composicion cosmetica o farmaceutica, particularmente dermatologica, destinada a favorecer la pigmentacion de la piel o de los cabellos, que contiene un extracto de cyperus y su procedimiento de fabricacion.
ES2003605A6 (es) Procedimiento de obtencion de una composicion farmaceutica particularmente dermatologica o cosmetica a base de fases laminares lipidicas hidratas o de liposomas que contienen un retinoide o un analogo estructural de dicho retinoide tal como un carotenoide.
ES2056762T1 (es) Composicion cosmetica o dermatologica bifasica para el desmaquillado, la limpieza el cuidado de la piel, conteniendo un cloruro de alquildimetilbenzilamonio.
ES8505632A1 (es) Procedimiento de preparacion de una composicion cosmetica que protege la epidermis humana contra los rayos ultravioletas
ES2044495T3 (es) Composicion cosmetica para el cuidado de los cabellos y utilizacion de dicha composicion.
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
MX9305118A (es) La utilizacion de un ecdisteroide para la preparacion de composiciones cosmeticas o dermatologicas destinadas especialmente para reforzar la funcion de barrera hidrica de la piel, o para la preparacion de un medio de cultivo de las celulas de la piel
NO921875D0 (no) Metallpeptidpreparater og fremgangsmaater for aa stimulere haarvekst
ES2195461T3 (es) Uso de acido salicilico para regular las arrugas de la piel y/o atrofia de la piel.
IT1191197B (it) Composizioni cosmetiche contenenti derivati idrossilati del dibenzoil metano e loro impiego per la protezione dell epidermide umana contro i raggi ultravioletti derivati idrossilati del dibenzoilmetano utilizazti in tali composizioni e procedimento per la loro preparazione
ES2086617T3 (es) Composicion cosmetica dermatologica a base de mezclas polivitaminicas.
ES2059297T1 (es) Utilizacion de saponinas de medicago para la preparacion de composiciones cosmeticas o farmaceuticas, particularmente dermatologicas que favorecen la renovacion de la epidermis, estimulan el rebrote del cabello o retardan su caida.
ES2090546T3 (es) Composicion cosmetica anhidra de maquillaje que comprende una fase grasa, y procedimiento de tratamiento cosmetico que utiliza esta composicion.
ES2153858T3 (es) Composicion antiacneica que contiene un extracto de poria cocos wolf.
ES2062767T3 (es) Preparados cosmeticos que contienen un extracto de cabezuelas de girasol (helianthus annuus).
IT8768027A0 (it) Derivati di 1 piperazinil pirimidina loro preparazione e impiego in terapia e cosmesi
ES2038270T3 (es) Preparaciones topicas sebosupresoras.
ES2129014B1 (es) Utilizacion de un extracto de eriobotrya japonica, especialmente en el campo de la cosmetica, para estimular la sintesis de los glicosaminoglicanos.
ES2182374T3 (es) Preparaciones cosmeticas acuosas en forma de barra.
ES2092916T3 (es) Composicion cosmetica que contiene en asociacion una superoxido dismutasa y una porfirina.
GR890100404A (el) Καλλυντικες συνθεσεις και συνθεσεις περιποιησεων του δερματος
DK1014934T3 (da) Anvendelse af mindst en ekstrakt af slægten Chrysanthenum til fremme af pigmenteringen af huden og/eller håret
MY101703A (en) Cosmetic
AR009763A1 (es) Utilizacion en una composicion como estimulador de tirosinasa de al menos un derivado de 3-oxido pirimidina, sustituido en la posicin 6

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 502043

Country of ref document: ES